choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Palivizumab

Palivizumab Newsletter
  • Infectious Disease Treatments on FDA’s Watchlist for Q2 2025 01 Apr 2025 17:58 GMT

    … 2025, the FDA is reviewing treatments in infectious disease … RSV). The treatment reduced RSV-associated medically attended lower … Phase 3 trial comparing Clesrovimab with Palivizumab in high- … trials, Innoviva Specialty Therapeutics plans to submit a New Drug

  • Intas Pharmaceutical Gets CDSCO Panel Nod to study Vedolizumab Powder for Concentrate for Solution for Infusion 09 Feb 2025 21:59 GMT

    Drug Standard Control Organization (CDSCO) to conduct the Phase I clinical trial … clinical trial titled “A randomized, double-blind, three-treatment, balanced … 53) of Intas Pharmaceuticals Limited, India with Entyvio … to study Palivizumab solution for injection

  • Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial 30 Jan 2025 18:57 GMT

    … the US Food and Drug Administration (FDA) in October 2024. … 47;AbbVie‘s Synagis (palivizumab), a mAb only used … Trials Arena. Elsewhere in the RSV space, US company Blue Lake Biotechnology … I/IIa trial. Meanwhile, Enanta Pharmaceuticals has reported positive …

  • AstraZeneca gets CDSCO Panel nod to study Palivizumab solution for injection 27 Jan 2025 22:17 GMT

    … the drug major AstraZeneca to conduct the study of Palivizumab solution … to a group of medicines known as immunizing agents. … the condition that clinical trial sites should be geographically … sites. Also Read: Exemed Pharmaceutical Gets CDSCO Panel Nod To …

  • RSV Vaccines and Treatments Face Global Access Hurdles 07 Jan 2025 10:28 GMT

    … the US Food and Drug Administration (FDA) in July 2023. … However, Midulla said that pharmaceutical companies are pushing to … to healthcare and supportive treatments, such as supplemental oxygen … well as the MEDLEY trial of palivizumab. All funding for these …

  • Govt funding expands pharmac medicine access 01 Jan 2025 18:09 GMT

    … four years to enhance medicine availability. “Pharmac operates … in negotiating deals with pharmaceutical companies, ensuring the … who have previously undergone treatment. HER2-positive metastatic … children, the funding of Palivizumab (Synagis) offers relief …

  • New Year, New Medicines 31 Dec 2024 20:13 GMT

    … people who have received other treatments previously. “Patients with HER2-positive … trastuzumab deruxtecan (branded as Enhertu). “Palivizumab (branded as Synagis) will also … entity responsible for deciding which medicines and medical devices are funded in …

  • FDA Accepts Biologics License Application for Infant RSV Antibody 17 Dec 2024 23:25 GMT

    The FDA has accepted a biologics … release. The FDA has also set a Prescription Drug User Fee Act … trial evaluating the effectiveness of clesrovimab compared to Merck’s competition, palivizumab … Abrysvo was approved by the FDA to prevent lower respiratory tract …

  • FDA Accepts Merck’s BLA for Clesrovimab 17 Dec 2024 22:49 GMT

    … season. The FDA has set a Prescription Drug User Fee … efficacy of clesrovimab versus palivizumab in infants and children … disease. Data from these trials were presented during IDWeek … get special offers from American Pharmaceutical Review – all delivered right …

  • FDA Accepts Merck's BLA for Clesrovimab, an Investigational mAb Against RSV in Infants 17 Dec 2024 17:05 GMT

    … to Merck. In clinical trials clesrovimab is being studied … a randomized placebo-controlled trial evaluating a single … incidence of RSV-associated medically attended lower respiratory infections … for clesrovimab and palivizumab and no drug-related serious AEs …

Satisfied with the content?

Continue to create your account.